Company News
Alkermes Shares Up 3% After Narcolepsy Trial
Alkermes Plc stock jumped 3.1% after its phase‑2 Vibrance‑2 trial of alixorexton met primary endpoints in narcolepsy type 2 patients.
The study enrolled 93 adults, showing dose‑dependent sleep‑latency
